Strategic Research

GPCR Drug Discovery group of GRIB

The GPCR Drug Discovery group focuses on the functionality of G protein coupled receptors (GPCRs) in the context of CNS-related disorders taking into account receptor plasticity, activation mechanism, signaling bias, ligand binding and the effect of the membrane and other interaction partners. The final goal is to translate obtained molecular insights into the design of drug candidates with improved therapeutic profiles.

The current reseach lines of the group are:

  • In-silico Multi-Receptor Profiling of Antipsychotic Drugs 
  • GPCR Dimers as Drug Target for the Treatment of Schizophrenia 
  • Membrane Lipid-Mediated Effects on GPCRs

The GPCR Drug Discovery group of GRIB, led by Jana Selent, is integrated in the Research Programme on Biomedical Informatics, GRIB. The GRIB is a joint research programme of the Hospital del Mar Medical Research Institute (IMIM) and the Department of Experimental and Health Sciences of the Universitat Pompeu Fabra. The GRIB mission is to develop and apply computational methods and information technologies for a better understanding and prediction of biological phenomena, giving especial emphasis to those related to the human diseases, their prevention, diagnosis and pharmacological treatment.  

Main projects

  • 1.

    La modulación alostérica del receptor D2 de la dopamina forma parte del mecanismo de acción del litio: de la evidencia molecular a la neuroimagen funcional

    2016-2018 (FIS)



Bioinformatics expertise:

Group Leader:

Jana Selent



Chus Donlo